Dimerized Knottin Peptides via Oxime Conjugation for Integrin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptides targeting integrins, such as αvβ3, αvβ5, and α5β1, have limited therapeutic efficacy due to their relatively low binding affinity and stability, necessitating the development of peptides with enhanced binding strength and specificity for cancer therapy applications.
Innovation Solution
Engineered knottin mini-proteins incorporating a non-natural amino acid with an aminooxy side chain are dimerized through chemoselective oxime conjugation, using a linker molecule to create multimeric peptides with increased binding affinity to integrin receptors, and conjugated with therapeutic agents like doxorubicin for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If conventional peptides are used to target integrins, then they can bind to integrin receptors, but their binding affinity and therapeutic efficacy are limited
Solution Approach 1:
The patent combines multiple knottin peptides into dimeric structures through disulfide bond formation, merging two binding units into one molecule. This doubling of binding units significantly enhances binding affinity to integrin receptors, directly resolving the contradiction between limited binding strength and therapeutic efficacy of conventional monomeric peptides
Solution Approach 2:
The invention creates composite peptide structures by hybridizing different knottin scaffolds (e.g., EETI-II and AgRP) to form dimeric peptides with combined properties. These composite structures exhibit enhanced binding affinity and therapeutic efficacy compared to individual parent peptides, overcoming the limitations of conventional single-structure peptides
2Adaptability or versatility
If peptide scaffolds are used for integrin targeting, then they can be engineered with specific binding motifs, but their stability in harsh conditions is insufficient
Solution Approach 1:
The patent introduces non-natural amino acids with specific local properties (e.g., hydroxamate side chains) at strategic positions within the knottin structure. These localized modifications enhance binding specificity to integrin receptors while the overall disulfide-constrained knottin framework maintains structural stability in harsh conditions, resolving the contradiction between adaptability and stability
3Strength
If low molecular weight scaffolds are dimerized, then binding strength increases by orders of magnitude, but larger peptide scaffolds show only several fold increase
Solution Approach 1:
The patent segments the peptide structure into distinct functional domains: stable disulfide-constrained knottin cores that provide structural integrity, and engineered binding loops containing RGD motifs that provide integrin specificity. This segmentation allows the dimeric structures to achieve significant binding strength enhancement while maintaining manageable size and complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dimerized knottin peptides demonstrate significantly improved binding strength and therapeutic efficacy, with enhanced ability to inhibit cell adhesion and proliferation, and facilitate targeted drug delivery to cancer cells, as evidenced by increased IC50 values and cytotoxicity assays.
Implementation Method 1
Engineered knottin mini-proteins incorporating a non-natural amino acid with an aminooxy side chain are dimerized through chemoselective oxime conjugation
Implementation Method 2
Knottins have a disulfide-bonded framework and triple-stranded beta-sheet fold that often provides remarkable stability in harsh conditions
Data Source
AI summary
Disclosed are knottin peptides containing non-natural amino acids so that they can be formed by chemical conjugation into two or more knottin monomers. The knottin monomers comprise a non-natural amino acid such as an aminooxy residue within the polypeptide sequence. The exemplified dimers were produced by oxime formation between two aldehyde groups present on a polyether linker and an aminooxy functional group that was site-specifically incorporated the knottin. Knottins variants based on EETI (Ecballium elaterium trypsin inhibitor) and AgRP (Agouti-related protein) were engineered to contain integrin-binding loops. These dimers were shown to have increased binding strength to integrins on U87MG tumor cells, achieving significant increases in inhibition of cell adhesion and proliferation. Also disclosed are knottin monomers comprising an aminooxy residue; these may be conjugated to molecules such as doxorubicin.